Why the study?
Does low-molecular-weight heparin reduce thromboembolic events and bleeding complications compared to unfractionated heparin in patients undergoing abdominal surgery?
Does low-molecular-weight heparin reduce thromboembolic events and bleeding complications compared to unfractionated heparin in patients undergoing abdominal surgery?
A low dose of LMWH (1750 anti-Xa IU daily) is as effective as UFH for postoperative VTE prophylaxis in abdominal surgery, with a significantly lower risk of bleeding.
Answers are grounded in this paper and cite their sources.
LMWH preferred over UFH for VTE prophylaxis after abdominal surgery to reduce bleeding; reinforces its role as first-line agent in perioperative care.
A randomized, double-blind multicenter trial was performed to compare the safety and efficacy of a new low-molecular-weight heparin (LMWH) (LU 47311, Clivarine) and standard unfractionated heparin for the prophylaxis of postoperative venous thromboembolism. Altogether 1351 patients scheduled to undergo abdominal surgery were included. Main outcome measures included the incidence of thromboembolic events (deep vein thrombosis, pulmonary embolism, or both) and bleeding complications, including wound hematoma. A total of 655 patients received 1750 anti-Xa IU of LMWH plus a placebo injection daily; 677 patients received 5000 IU of unfractionated heparin (UFH) twice a day. Both drugs were found to be equally effective, as 4.7% of patients in the LMWH group and 4.3% in the UFH group developed postoperative thromboembolic complications. However, the incidence of bleeding complications was significantly reduced in the LMWH group: 55 (8.3%) patients in the LMWH group and 80 (11.8%) in the UFH group developed bleeding complications, a relative risk (RR) of 0.70 (95% CI 0.51-0.97;p = 0.03); wound hematoma occurred in 29 (4.4%) of the LMWH group compared with 55 (7.7%) in those in the UFH group for an RR of 0.57 (95% CI 0.37-0.88;p = 0.01). This study confirmed that a very low dose of 1750 anti-Xa IU daily of this new LMWH is as effective as 10,000 IU of UFH for preventing postoperative deep vein thrombosis. At this dose its administration is associated with a significant reduction in the risk of bleeding including wound hematoma.
No takes yet. Share an insight, caveat, or question.
Kakkar et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: